PEG-PLGA nanoparticles deposited in Pseudomonas aeruginosa and Burkholderia cenocepacia
Open Access
- 26 January 2024
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 14 (12) , 100939
Abstract
No abstract availableKeywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (13N15467)
- Federal Ministry of Education and Research Berlin Office
- German Research Foundation (PL320/3-2, FI899/4-2, MU4251/1-2)
This publication has 21 references indexed in Scilit:
- ECFS best practice guidelines: the 2018 revisionJournal of Cystic Fibrosis, 2018
- Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cellsInternational Journal of Pharmaceutics, 2017
- Cell Fractionation of Pseudomonas aeruginosaBio-Protocol, 2013
- Development of Nanoparticles for Antimicrobial Drug DeliveryCurrent Medicinal Chemistry, 2010
- Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storageEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Aminoglycosides: Activity and ResistanceAntimicrobial Agents and Chemotherapy, 1999
- Burkholderia (formerly Pseudomonas) cepacia porin is an oligomer composed of two component proteinsMicrobiology, 1994
- Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistanceMolecular Microbiology, 1991
- Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosisPediatric Pulmonology, 1991
- Tobramycin resistance of mucoid Pseudomonas aeruginosa biofilm grown under iron limitationJournal of Antimicrobial Chemotherapy, 1989